Skip to main content
Erschienen in: Endocrine 1/2012

01.08.2012 | Editorial

COPD and osteoporosis: something more than a comorbidity

verfasst von: Claudio Tantucci

Erschienen in: Endocrine | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

Chronic obstructive lung disease (COPD) is a progressive functional disorder of the respiratory system with high prevalence in the older population and is presently the fourth cause of mortality and supposed to be the third in the 2020 in the world [1]. Large part of COPD morbidity and mortality is due to extra-pulmonary effects rather than pulmonary consequences of this disorder, mainly when the airway obstruction is mild or moderate [2]. Among the extra-pulmonary effects, osteopenia and osteoporosis, as a consequence of a loss of bone mineral density (BMD), have been widely recognized as a major comorbidity in COPD patients [3]. …
Literatur
1.
Zurück zum Zitat K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. Weel, J. Zelinski, Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007)PubMedCrossRef K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. Weel, J. Zelinski, Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007)PubMedCrossRef
2.
Zurück zum Zitat P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C.R. Jenkins, P.W. Jones, J.C. Yates, J. Vestbo, Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive lung disease. N. Engl. J. Med. 356, 775–789 (2007)PubMedCrossRef P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C.R. Jenkins, P.W. Jones, J.C. Yates, J. Vestbo, Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive lung disease. N. Engl. J. Med. 356, 775–789 (2007)PubMedCrossRef
3.
Zurück zum Zitat G.T. Ferguson, P.M.A. Calverely, J.A. Anderson, C.R. Jenkins, P.W. Jones, R.L. Willits, J.C. Yates, J. Vestbo, B. Celli, Prevalence and progression of osteoporosis in patients with COPD. Chest 136, 1456–1465 (2009)PubMedCrossRef G.T. Ferguson, P.M.A. Calverely, J.A. Anderson, C.R. Jenkins, P.W. Jones, R.L. Willits, J.C. Yates, J. Vestbo, B. Celli, Prevalence and progression of osteoporosis in patients with COPD. Chest 136, 1456–1465 (2009)PubMedCrossRef
4.
Zurück zum Zitat A. Jebouck, S. Boonen, M. Decramer, W. Janssens, COPD, bone metabolism and osteoporosis. Chest 139, 648–657 (2011)CrossRef A. Jebouck, S. Boonen, M. Decramer, W. Janssens, COPD, bone metabolism and osteoporosis. Chest 139, 648–657 (2011)CrossRef
5.
Zurück zum Zitat B. Lind, Y. Feng, The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine (2012). doi:10.1007s12020-011-9583 B. Lind, Y. Feng, The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine (2012). doi:10.​1007s12020-011-9583
6.
Zurück zum Zitat H. Watz, B. Waschki, A. Kristen, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, H. Magnussen, The metabolic syndrome in patients with chronic bronchitis and COPD. Chest 136, 1039–1104 (2009)PubMedCrossRef H. Watz, B. Waschki, A. Kristen, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, H. Magnussen, The metabolic syndrome in patients with chronic bronchitis and COPD. Chest 136, 1039–1104 (2009)PubMedCrossRef
7.
Zurück zum Zitat T.C. Mineo, V. Ambrogi, D. Mineo, A. Fabbri, E. Fabbrini, R. Massoud, Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 127, 1960–1966 (2005)PubMedCrossRef T.C. Mineo, V. Ambrogi, D. Mineo, A. Fabbri, E. Fabbrini, R. Massoud, Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 127, 1960–1966 (2005)PubMedCrossRef
8.
Zurück zum Zitat S.R. Majumdar, C. Villa-Roel, K.J. Lyons, B.H. Rowe, Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Resp. Med. 104, 260–266 (2010)CrossRef S.R. Majumdar, C. Villa-Roel, K.J. Lyons, B.H. Rowe, Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Resp. Med. 104, 260–266 (2010)CrossRef
9.
Zurück zum Zitat R.A. Harrison, K. Siminoski, D.B. Vethanayagam, S.R. Majumdar, Osteoporosis related kyphosis and impairments in pulmonary function: a systematic review. J. Bone Miner. Res. 22, 247–257 (2007) R.A. Harrison, K. Siminoski, D.B. Vethanayagam, S.R. Majumdar, Osteoporosis related kyphosis and impairments in pulmonary function: a systematic review. J. Bone Miner. Res. 22, 247–257 (2007)
10.
Zurück zum Zitat G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef
Metadaten
Titel
COPD and osteoporosis: something more than a comorbidity
verfasst von
Claudio Tantucci
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9686-z

Weitere Artikel der Ausgabe 1/2012

Endocrine 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.